Skip to main content
SpringerLink
Log in

Clinical Trials Report

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin converting inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997.

    Article  Google Scholar 

  2. Wassertheil-Smoller S, Psaty B, Greenland P, Oberman A, et al.: Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA 2004, 292:2849–2859.

    Article  PubMed  CAS  Google Scholar 

  3. Tardif JC, Duchrome A, Yuh A, et al.: Retrospective longitudinal cohort study comparing the effects of angiotensin-converting enzyme inhibitors and long-acting calcium channel blockers on total and cardiovascular mortality in patients with hypertension. Clin Ther 2004, 26:1073–1083.

    Article  PubMed  CAS  Google Scholar 

  4. Julius S, Kjeldsen SE, Weber M, et al.: VALUE Trial Group. Out omes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004, 363:2022–2031.

    Article  PubMed  CAS  Google Scholar 

  5. Nissen SE, Tuzcu EM, Libby P, et al.: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. JAMA 2004, 292:2217–2226.

    Article  PubMed  CAS  Google Scholar 

  6. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al., for the INVEST investigators: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. JAMA 2003, 290:2805–2816.

    Article  PubMed  CAS  Google Scholar 

  7. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med 2000, 342:142–153.

    Google Scholar 

  8. Fox KM, European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: a randomized, double-blind, placebo-controlled, multi-centre trial (the EUROPA study). Lancet 2003, 362:782–788.

    Article  PubMed  CAS  Google Scholar 

  9. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23(Suppl 2):B54-B64.

    PubMed  Google Scholar 

  10. Weir MR, Hall PS, Behrens MT, et al.: Salt and blood pressure responses to calcium antagonism in hypertensive patients. Hypertension 1997, 30:422–427.

    PubMed  CAS  Google Scholar 

  11. Blood Pressure Trialists’ Collaboration: Effect of ACE inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000, 355:1955–1964.

    Article  Google Scholar 

  12. Bestehorn HP, Neuman FJ, Buttner HJ, et al.: Evaluation of the effect of oral verapamil on clinical outcomes and angiographic restenosis after percutaneous coronary intervention: the randomized double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Vascular Events after Angioplasty (VESPA) trial. J Am Coll Cardiol 2004, 43:2160–2165.

    Article  PubMed  CAS  Google Scholar 

  13. Mason RP: Mechanisms of plaque stabilization for dihydropyridine calcium channel blocker amlodipine: a review of the evidence. Atherosclerosis 2002, 165:191–199.

    Article  PubMed  CAS  Google Scholar 

  14. da Cunha V, Tham DM, Martin-McNulty B, et al.: Enalapril attenuates angiotensin II-mediated atherosclerosis and vascular inflammation. Atherosclerosis 2005, 178:9–17.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. John M. Flack MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Flack, J.M. Clinical Trials Report. Current Science Inc 7, 165–167 (2005). https://doi.org/10.1007/s11906-005-0004-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-005-0004-5

Keywords

Search

Navigation